Role of hypertension in the metabolic syndrome: Who is affected?

Current Hypertension Reports

Volumn 7, Issue 6, 2005, Pages 418-426

  Velarde, Gladys ^a   Berk, Bradford C ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; METFORMIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT;

AFRICAN AMERICAN; ATHEROSCLEROSIS; BODY FAT; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; EPIDEMIC; ETHNIC GROUP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KINESIOTHERAPY; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REVIEW; SYNDROME DELINEATION; UNITED STATES;

HUMANS; HYPERTENSION; INCIDENCE; LIPIDS; METABOLIC SYNDROME X; RISK FACTORS; UNITED STATES;

EID: 31344462460     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0036-x     Document Type: Review

References (75)

1. Reaven GM: Abnormal lipoprotein metabolism in non-insulin-dependent diabetes mellitus: pathogenesis and treatment. Am J Med 1987, 83:31-40.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2496.
3. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
4. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease, among NHANES III participants age 50 years and older. Diabetes 2003, 52:121-214.
5. Isomaa B, Almgren P, Tuomi T, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
6. Trevisan M, Liu J, Bahsas FB, Menotti A: Syndrome X and mortality: a population-based study. Am J Epidemiol 1998, 148:958-966.
7. Ferrannini E, Buzzigoli G, Bonaonna R, et al.: Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350-357.
8. Grundy SM: Inflammation, hypertension, and the metabolic syndrome. JAMA 2003, 290:3000-3002.
9. Ohlson LO, Larsson B, Svardsudd K, et al.: The influence of body fat distribution on the incident of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985, 34:1055-1058.
10. Sironi AM, Gastaldelli A, Mari A, et al.: Visceral fat in hypertension influence on insulin resistance and B-cell function. Hypertension 2004, 44:127-133.
11. Wolk R, Shamsuzzaman AS, Somers V. Obesity, sleep apnea and hypertension. Hypertension 2003, 42:1067-1074.
12. Landsberg L: Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. N Engl J Med 1996, 61:1081-1090.
13. Poirier P, Lemieux I, Mauriege P, et al.: The Quebec Health Survey. Hypertension 2005, 45:363-367.
14. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and the sympathetic nervous system. Am J Hypertens 2001, 14:103s-111s.
15. Hall JE, Crook ED, Jones DW, et al.: Mechanism of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137.
16. Rahmouni K, Correia MLG, Haynes WG, et al.: Obesity-associated hypertension. Hypertension 2005, 45:9-14.
17. Haynes WG, Morgan DA, Djalai A, et al.: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999, 17:1949-1953.
18. Hall JE, Kuo JJ, da Silva AA, et al.: Obesity-associated hypertension and kidney disease. Curr Opin Nephrol 2003, 12:195-200.
19. Beltowski J, Wojcicka G, Marciniak A, et al.: Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci 2004, 74:2987-3000.
20. Iwashima Y, Katsuya T, Ishikawa K, et al.: Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
21. Kojima S, Funahashi T, Sakamoto T, et al.: The variations of plasma concentrations of a novel adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 2003, 89:667-668.
22. Poykko SM, Kellokoski E, Horkko S, et al.: Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52:2546-2553.
23. Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609-611.
24. Masuzaki H, Yamamoto H, Kenyon CJ, et al.: Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003, 112:83-90.
25. Nielsen S, Halliwill JR, Joyner MJ, et al.: Vascular response to angiotensin II in upper-body obesity. Hypertension 2004, 44:436-441.
26. Steinberg HO, Chaker H, Leaming R, et al.: Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension 1996, 97:2601-2610.
27. Egan BM, Hennes MM, Stepniakowski K, et al.: Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension 1996, 27:7223-7728.
28. Goodfriend TL, Calhoun DA: Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004, 43:518-524.
29. de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41-47.
30. Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity: associated cardiovascular and renal disease. Am J Med Sci 2002, 323:127-137.
31. Hengegar JR, Bigle SA, Hengegar LK, et al.: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001, 12:1211-1217.
32. Dwyer TM, Banks SA, Alonso-Galicia M, et al.: Distribution of renal medullary hyaluronan in lean and obese rabbits. Kidney Int 2000, 58:721-729.
33. Nieto FJ, Young TB, Lind BK, et al.: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000, 283:1829-1836.
34. Fournier AM, Gadia MT, Kubrusly DB, et al.: Blood pressure, insulin, and glycemia in nondiabetic subjects. Am J Med 1986, 80:861-864.
35. Donahue RP, Orchard TJ, Becker DJ, et al.: Sex differences in the coronary heart disease risk profile: a possible role for insulin: the Beaver county study. Am J Epidemiol 1987, 125:650-657.
36. Skarfors ET, Lithell HO, Selinus I: Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 1991, 9:217-223.
37. Lissner L, Bengtsson C, Lapidus L, et al.: Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992, 20:797-801.
38. Taittonen I, Uhari M, Nuutinen M, et al.: Insulin and blood pressure among healthy children. Am J Hypertens 1996, 9:193-199.
39. Raitakari OT, Porkka KVK, Ronnemaa T, et al.: The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. Diabetologia 1995, 38:1042-1050.
40. Liese AD, Mayer-Davis EJ, Chambless LE, et al.: Elevated fasting insulin predicts incident hypertension: the ARIC study. J Hypertens 1999, 17:1169-1177.
41. Saad MF, Lillioja S, Nyomba BL, et al.: Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1993, 324:733-9.
42. Saad MF, Rewers M, Selby J, et al.: Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension 2004, 43:1324-1331.
43. Collins VR, Dowse GK, Finch CF, Zimmet PZ: An inconsistent relationship between insulin and blood pressure in three Pacific Island populations. J Clin Epidemiol 1990, 43:1369-1378.
44. Reaven GM: Insulin resistance/compensatory hyperinsulinimia, essential hypertension and cardiovascular disease. J Clin Endocrinol Metab 2003, 88:2399-2403.
45. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
46. Wheatcrosft SB, Williams IL, Shah AM, Kearney MT: Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003, 20:255-268.
47. Avid A, Gardner J: Racial differences in ion regulation and their possible links to hypertension in blacks. Hypertension 1989, 14:585-589.
48. Falkner B, Kushner H, Levison S, Canessa M: Albuminuria in association with insulin and sodium-lithium countertransport in young African Americans with borderline hypertension. Hypertension 1995, 25:1315-1321.
49. Carnethon MR, Loria CM, Hill JO, et al.: Risk factors for the metabolic syndrome. The Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 2004, 27:2707-2715.
50. Frontini MG, Srinivasan SF, Elkasabany A, Berenson GS: Distribution and cardiovascular risk correlates of serum triglycerides in young adults from a biracial community. The Bogalusa Heart Study. Atherosclerosis 2001, 158:201-209.
51. Jessepen J, Ole Heim H, Svadicani P, Gynterberg F: Low triglycerides-high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001, 161:361-366.
52. Davis TME, Cull CA, Holman RR: Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes. Diabetes Care 2001, 24:1116-1174.
53. Sesso HD, Baring JE, Rifai N, et al.: C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945-2951.
54. King DE, Egan BM, Mainous III AG, Geesey ME: Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens 2004, 6:562-568.
55. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004, 44:6-11.
56. Tsikouris JP, Suarez JA, Simoni JS, et al.: Exploring the effects of ACE inhibitor, tissue penetration on vascular inflammative following acute myocardial infarction. Coronary Artery Dis 2004, 15:211-217.
57. Curtin PD: The slavery hypothesis for hypertension among African Americans: the historical evidence. Am J Public Health 1992, 82:1681-1686.
58. Wolz M, Cutler J, Rocella EJ, et al.: Statement from the National High Blood Pressure Education Program: prevalence of hypertension. Am J Hypertens 2000, 13:103-104.
59. Park YW, Zhu S, Polaniappan L, et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003, 163:427-436.
60. He J, Kag MJ, Caballero B, et al.: Plasma insulin levels and incidence of hypertension in African Americans and whites. Arch Intern Med 1999, 159:498-503.
61. Kountz D: Hypertension in ethnic population tailoring treatments. Clin Cornerstone 2004, 6:39-48.
62. Jha P, Enas EA, Yusuf S: Coronary artery disease in Asian Indians, prevalence and risk factors. Asian Am Pac Isl J Health 1993, 1:163-175.
63. Ramachandran A, Snehalatha C, Latha E, et al.: Clustering of cardiovascular risk factors in urban Asian Indians. Diabetes Care 1998, 21:967-971.
64. Singh RB, Niaz MA, Ghosh S, et al.: Epidemiological study of coronary artery disease and its risk factors in an elderly urban population of north India. J Am Coll Nutr 1995, 14:628-634.
65. Narkiewicz K, Phillips BG, Kator M, et al.: Gender-selective interactions between aging, blood pressure, and sympathetic nerve activity. Hypertension 2005, 45:522-525.
66. Grundy SM, Hansen B, Smith SC Jr, et al.: Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 2004, 109:551-556.
67. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 2002, 346:393-403.
68. Van Gaol LF, Rissanen AM, Scheen AJ, et al.: RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
69. Wang TD, Chen WJ, Lin JW, et al.: Effects of rosiglitazone on endothelial function, C-reactive protein, and component of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004, 93:362-365.
70. Szapary P, Bloedon L, Samaha FF, et al.: The effects of pioglitazone on lipoproteins in non-diabetics with metabolic syndrome: results from a randomized controlled trial. Program and abstracts of the 65th Scientiflc Session of the American Diabetes Association; San Diego, CA. June10-14, 2005, Abstract 963-P.
71. Kim DK, Young JA, Park M, et al.: The effects of combination therapy with exercise and fenofibrate for the metabolic syndrome in rats. Program and abstracts of the 65th Scientific Session of the American Diabetes Association; San Diego, CA. June 10-14, 2005, Abstract 1794.
72. Collins R, Peto R, Mac Mahon S, et al.: Blood pressure, stroke and coronary heart disease. Part 2: Short term reductions in blood pressure, overview of randomized drug trials in their epidemiological context. Lancet 1990, 335:827-838.
73. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:1981-1997.
74. Lindholm LH, Persson M, Alaupovic P, et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003, 21:1563-1574.
75. Verdecchia P, Gianpaolo R, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.